The PBM's negotiated prices with Lilly and Amgen were confidential, but clearly Teva was unable to talk its way onto the formulary—a setback that likely fueled much of the talk about Ajovy during the earnings call. Both Schultz and O'Brady said they aren't worried. "We have an enormous unmet need, a huge patient pool and a very good early launch," Schultz said. RELATED: Teva's patent failure gives long-acting Copaxone generics free rein Perhaps, but Ajovy worries are only compounded by sales declines for both Copaxone and Teva's flagship generics business.